leadf
logo-loader
viewAntev Limited

Regulators give Antev a clear pathway to regulatory approval

Regulators give Antev a clear pathway to regulatory approval

Amit Kohli has been at the helm of Antev for less than two months, but the new chief executive has already devised a strategy for the clinical-stage biopharmaceutical company to establish its product teverelix TFA, as the gold standard treatment in its indications.

Those indications include prostate cancer, benign prostatic hyperplasia, acute urinary retention for men and in women endometriosis and uterine fibroids. Kohli says regulators at both the FDA and EMA have given the company ' a clear pathway to regulatory approval.' He describes those discussions about a single arm non-controlled trial as 'amazing.'

Antev is seeking funding which Kohli says includes an IPO possibly at Nasdaq Europe or US in parallel with trade deals.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Argo Blockchain CEO Peter Wall now paid in Bitcoin after record month in...

Argo Blockchain PLC's (LON:ARB) talks to Proactive London's Katie Pilbeam after announcing mining has now gone up to 129 Bitcoin (or equivalent) in February, up from 93 in January. Mining revenue in February amounted to £4.34mln, compared to January’s £2.48mln. At the end of February, the...

8 hours, 31 minutes ago

2 min read